Skip Navigation
Back to Search Innovations
Prevention of Glucocorticoids-Induced Muscle Atrophy and/or Enhancement of Muscle Regeneration Via Neutrophil Elastase Inhibition
A novel therapeutic approach to treating muscular dystrophies by enhancing muscle regeneration, function and fiber size
Please note, header image is purely illustrative. Source: Prof. Peter Brophy, Wellcome collection, CC BY 4.0.


Muscular dystrophy encompasses more than 30 inherited diseases characterized by muscle weakness and muscle loss. All forms of muscular dystrophy are progressive and deteriorating. At the moment, there is no cure for muscular dystrophy. Available treatments aim to alleviate symptoms and prevent complications. Low dose corticosteroids such as prednisone may help to maintain muscle tone however there are serious side effects associated with the long term use of these drugs. New disease modifying medications are sorely needed to help patients with muscular dystrophy.


Researchers at Stony Brook University have identified elastase as a target for therapeutic intervention in muscular dystrophy. She has shown that elastase levels and activity are elevated in dystrophic muscle which leads to impairment of myoblast survival, proliferations and differentiation. Importantly, in vivo data demonstrates that inhibiting elastase activity in a dystrophic animal model leads to an increase in grip strength and muscle fiber size. In addition, elastase inhibition results in a decrease in fibrosis and inflammation around the muscle fibers, which are both thought to be important contributors to the long term progression of the disease. Further Details: - Arecco et al. Sci Rep. 2016 May 31;6:24708


-Increases muscle regeneration, muscle size, muscle function -Reduces inflammation and fibrosis -Clinical use of elastase inhibitors has been shown to be safe -Potential companion diagnostic available


- Muscular Dystrophy - Duchenne Muscular Dystroph


Addolorata Pisconti, Associate Professor, Biochemistry and Cell Biology

Licensing Potential

Development partner,Licensing

Licensing Contact

Sean Boykevisch, Director, Intellectual Property Partners,, 6316326952


Tech Id